logo

Press Releases

    • 02 SEP 2015

    PharmaCyte Biotech Executives Interviewed on Role of Leaders in Oncology for Development of Its Clinical Trials

    SILVER SPRING, Md., Sept. 02, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and Chief Operating Officer, Dr. Gerald W. Crabtree, Ph.D., have

    Read more →
    • 25 AUG 2015

    PharmaCyte Biotech Announces Successful Completion of Interim Audit of GMP Facility for the Production of Cell-in-a-Box for Clinical Trials

    SILVER SPRING, MD, August 25, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, provided an update on the progress of completing the compliance process for Austrianova’s cGMP (current Good Manufacturing Practices-compliant) facility in

    Read more →
    • 06 AUG 2015

    PharmaCyte Biotech Updates Progress of cGMP Facility for the Production of Cell-in-a-Box for Clinical Trials

    SILVER SPRING, MD, August 6, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced an update on the progress of completing the certification of Austrianova’s cGMP (current Good Manufacturing Practices-compliant) facility in the

    Read more →
    • 04 AUG 2015

    Chardan Releases Industry Report Covering PharmaCyte Biotech

    SILVER SPRING, MD, August 4, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chardan Capital Markets LLC, a privately held full service global investment bank specializing in micro, small and

    Read more →
    • 23 JUL 2015

    PharmaCyte Biotech Begins Second Follow-Up Study on Ascites

    SILVER SPRING, MD, July 23, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its follow-up study on ascites began this week. That study is being conducted by Translational Drug Development

    Read more →
    • 16 JUL 2015

    PharmaCyte Biotech Appoints Renowned Oncologist Dr. Manuel Hidalgo to Scientific Advisory Board

    SILVER SPRING, MD, July 16, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Dr. Manuel Hidalgo, one of Europe’s leading clinical and laboratory investigators in the field of pancreatic cancer,

    Read more →
    • 09 JUL 2015

    PharmaCyte Biotech Appoints American Stock Transfer as New Stock Transfer Agent

    SILVER SPRING, MD, July 9, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that, effective July 10, 2015, American Stock Transfer & Trust Company (“AST”) will replace Signature Stock Transfer as

    Read more →
    • 01 JUL 2015

    PharmaCyte Biotech Enters Into Research & Consulting Agreement

    PharmaCyte Biotech, Inc. recently announced it has signed a major Research Services Agreement and an important Consulting Contract with the University of Technology Sydney (UTS) in Australia. Both of these contracts concern the development of PharmaCyte Biotech’s treatment for insulin-dependent diabetes that is composed of proprietary human non-pancreatic insulin-producing cells (Melligen cells) that are to

    Read more →
    • 30 JUN 2015

    PharmaCyte Biotech Releases HealthWatch Segment Featured on Discovery Channel

    SILVER SPRING, MD, June 30, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its technology and treatments were featured on the Discovery Channel and ION Network this morning. Discovery Channel

    Read more →
    • 29 JUN 2015

    PharmaCyte Biotech’s Cancer and Diabetes Treatments Airing Nationwide on Discovery Channel

    PharmaCyte Story to Reach More Than 96 Million U.S. Households on June 30

    SILVER SPRING, MD, June 29, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its technology and treatments

    Read more →